SAN FRANCISCO, Sept. 12 /PRNewswire/ -- West Coast Biologicals, Inc. (WCB) described today the results of oral vaccination studies using novel delivery and adjuvant technology. West Coast Biologicals presented data on its technology for oral vaccination at the Second International Conference on Modern Vaccines Adjuvants & Delivery Systems in London. WCB described mouse studies using a toll-like receptor 3 agonist (double-stranded RNA) together with a nonreplicating adenovirus vector for oral vaccination. Using WCB's chimeric research vaccine, antibody responses were 100-fold higher than orally delivered rAd vaccine without adjuvant, and 35-fold higher than achieved by IM injection. WCB also reported a significant increase in expansion of antigen- specific CD8+ T-cells using their chimeric vaccine, compared to rAd5.
